Carl Zeiss Meditec AG has confirmed that Bronwyn Brophy O’Connor, currently CEO of the Vitrolife Group in Sweden, will take over as CEO of Carl Zeiss Meditec AG on December 1, 2026. On the same date, she will join the Executive Board of Carl Zeiss AG with responsibility for the Medical Technology segment. Her appointment as successor to current CEO Andreas Pecher had been first announced in May 2026. With the start date now confirmed, she will assume leadership of Carl Zeiss Meditec Group from Andreas Pecher, who has served as interim CEO since January 1, 2026.
The appointment matters for the medtech industry because Carl Zeiss Meditec is one of the world’s leading medical technology companies, supplying innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. The company offers complete solutions, including implants and consumables, to diagnose and treat eye diseases, and creates innovative visualization solutions in the field of microsurgery.
“I am delighted to join Carl Zeiss Meditec and the ZEISS Group. The company combines deep scientific expertise, close customer relationships and a strong commitment to improving patient care. I look forward to working with our teams and customers to build on these strengths, advance innovation and successfully shape the next stage of the company’s transformation,” said Bronwyn Brophy O’Connor.
“With Bronwyn Brophy O’Connor, Carl Zeiss Meditec is gaining an internationally experienced medtech executive who will bring a strong customer and innovation perspective to the company. We wish her a great start,” said Peter Kameritsch, Chairman of the Supervisory Board of Carl Zeiss Meditec AG.
“We would like to thank Andreas Pecher, both for his temporary dual role as CEO of the ZEISS Group and interim CEO of Carl Zeiss Meditec AG, and for providing important momentum during this period. With her excellent skills, Bronwyn Brophy O’Connor will now be able to further advance the strategy and transformation of the Medical Technology segment forward and contribute to the success of the ZEISS Group,” said Dr. Michael Bolle, Chairman of the Supervisory Board of Carl Zeiss AG.
Effective December 1, 2026, the Management Board of Carl Zeiss Meditec AG will comprise Bronwyn Brophy O’Connor as CEO and Justus Wehmer as CFO. The Executive Board of Carl Zeiss AG will comprise Andreas Pecher (President and CEO), Stefan Müller (CFO), Bronwyn Brophy O’Connor (Head of the ZEISS Medical Technology segment), Sven Hermann (Head of the ZEISS Consumer Markets segment), Dr. Frank Rohmund (Head of the ZEISS Semiconductor Manufacturing Technology segment), and Dr. Marc Wawerla (Head of the ZEISS Industrial Quality & Research segment).
Brophy O’Connor brings extensive international experience. She studied at Dublin City University in Ireland, earning a bachelor’s degree in International Marketing and Languages (Spanish and French) and completed her Master of Business Administration in 2002. She began her career at Johnson & Johnson in 1997, serving in roles of increasing seniority and ending as General Manager of the Cardiovascular Care Group for the U.K. & Ireland in 2012. She then joined Covidien, later acquired by Medtronic, serving from 2013 until 2018 as Vice President Early Technologies EMEA and later as President Women’s Health at Medtronic in Boston, USA. In 2019, she joined Thermo Fisher Scientific as President for the EMEA region and one year later was promoted to Global President of the Immunodiagnostics Division in Uppsala, Sweden. She has worked internationally, including in Ireland, Spain, the U.K., Switzerland, Sweden and the U.S. Since 2023, she has been CEO of the Vitrolife Group, a global medtech company publicly listed on the NASDAQ Stockholm and headquartered in Gothenburg, Sweden.
Andreas Pecher studied physics at the University of Würzburg, Germany, and the University of Texas at Austin, USA. He earned an MBA at the Kellogg School of Management and a Master of Engineering Management at the McCormick School of Engineering. He began his career at Motorola (today NXP) in Texas in 1998, worked at McKinsey & Company, and joined ZEISS in 2013. He became President and CEO of Carl Zeiss AG effective April 1, 2025, and took on the interim CEO role at Carl Zeiss Meditec on January 1, 2026.
Carl Zeiss Meditec AG, listed on the TecDAX and SDAX of the German stock exchange, has 5,784 employees worldwide and generated revenue of EUR 2,228m in fiscal year 2024/25. The Group’s head office is in Jena, Germany, with more than 50 percent of employees based in the USA, Japan, Spain and France. Around 39 percent of shares are in free float, with approx. 59 percent held by Carl Zeiss AG. For more information, visit www.zeiss.com/med. The original release is available on www.newmediawire.com.
